for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Ltd (ADR)

TEVA.N

Latest Trade

12.98USD

Change

0.23(+1.80%)

Volume

913,242

Today's Range

12.83

 - 

13.07

52 Week Range

6.07

 - 

13.76

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
12.75
Open
12.99
Volume
913,242
3M AVG Volume
360.22
Today's High
13.07
Today's Low
12.83
52 Week High
13.76
52 Week Low
6.07
Shares Out (MIL)
1,095.52
Market Cap (MIL)
14,143.03
Forward P/E
5.13
Dividend (Yield %)
--

Next Event

Teva Pharmaceutical Industries Ltd Annual Shareholders Meeting

Latest Developments

More

National Institutes Of Health Begins Clinical Trial Of Hydroxychloroquine And Azithromycin To Treat Covid-19

Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

Teva And Celltrion Healthcare Announce Launch Of TRUXIMA Injection

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Ltd (ADR)

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry

Biotechnology & Drugs

Contact Info

5 Bazel St, P O B 3190

49131

Israel

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Eliyahu Sharon Kalif

Chief Financial Officer, Executive Vice President

Mark Sabag

Executive Vice President, Chief Human Resources Officer and Global Communications and Brand

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.88 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.4K

2018

18.9K

2019

16.9K

2020(E)

16.8K
EPS (USD)

2017

4.010

2018

2.920

2019

2.400

2020(E)

2.510
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.83
Price To Book (MRQ)
1.04
Price To Cash Flow (TTM)
16.90
Total Debt To Equity (MRQ)
192.91
LT Debt To Equity (MRQ)
180.87
Return on Investment (TTM)
-2.00
Return on Equity (TTM)
-1.51

Latest News

Latest News

Israel's Teva gets China approval for Huntington's treatment

Teva Pharmaceutical said on Monday that China has given the go-ahead to its Austedo treatment for Huntington's disease.

Teva Pharm gets approval in China for Huntington's treatment

China has given the greenlight to Teva Pharmaceutical Industries' Austedo treatment for Huntington's disease, the company said on Monday.

Teva Pharmaceutical's profit beats forecasts, shares jump

Israel-based Teva Pharmaceutical Industries <TEVA.TA> beat first-quarter profit forecasts on Thursday, boosted by stronger demand for generic and over-the-counter drugs and respiratory treatments.

BRIEF-Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

* REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION

Teva Pharm Q1 profit beats forecasts, reaffirms 2020 outlook

Israel-based Teva Pharmaceutical Industries reported a higher-than-expected rise in first-quarter profit on Thursday, boosted by stronger demand for generic and over-the-counter drugs and respiratory products.

BRIEF-Inhalation Sciences Sweden Signs Contract With Teva Pharmaceuticals

* INHALATION SCIENCES SIGNS CRO CONTRACT WORTH 30.5 KEUR WITH GLOBAL PHARMACEUTICAL COMPANY

BRIEF-Teva And Celltrion Healthcare Announce Launch Of TRUXIMA Injection

* TEVA AND CELLTRION HEALTHCARE ANNOUNCE LAUNCH OF TRUXIMA® (RITUXIMAB-ABBS) INJECTION FOR RHEUMATOID ARTHRITIS, ONLY BIOSIMILAR TO RITUXAN® (RITUXIMAB) AVAILABLE IN UNITED STATES FOR THIS INDICATION

BRIEF-Teva Announces U.S. Launch Of Autoinjector For AJOVY Injection

* TEVA ANNOUNCES U.S. LAUNCH OF AUTOINJECTOR FOR AJOVY® (FREMANEZUMAB-VFRM) INJECTION Source text for Eikon: Further company coverage:

U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.

U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy.

BRIEF-Teva Pharmaceutical Industries Says CEO Kåre Schultz's FY 2019 Total Compensation Was $11.6 Mln

* TEVA PHARMACEUTICAL INDUSTRIES LTD SAYS CEO KÅRE SCHULTZ'S FY 2019 TOTAL COMPENSATION WAS $11.6 MILLION VERSUS $32.5 MILLION IN FY 2018 - SEC FILING

BRIEF-Teva And Celltrion Healthcare Announce U.S. Availability Of Herzuma For Injection

* TEVA AND CELLTRION HEALTHCARE ANNOUNCE U.S. AVAILABILITY OF HERZUMA® (TRASTUZUMAB-PKRB) FOR INJECTION Source text for Eikon: Further company coverage:

BRIEF-Teva Announces FDA Approval Of Armonair Digihaler Inhalation Powder

* TEVA ANNOUNCES FDA APPROVAL OF ARMONAIR® DIGIHALER™ (FLUTICASONE PROPIONATE) INHALATION POWDER

Teva Pharm CEO hopes to launch Huntington's drug in China this year

Israel-based Teva Pharmaceutical Industries hopes to receive approval to launch its Huntington's treatment Austedo in China this year, the company's chief executive said on Wednesday.

Teva Pharm regains market trust amid restructuring

Teva Pharmaceutical Industries <TEVA.TA> <TEVA.N> said on Wednesday that a two-year restructuring has enabled the world's largest generic drugmaker to turn a corner, as it reported slightly better than expected fourth-quarter results.

BRIEF-Teva Reports Qtrly Earnings Per Share $0.10

* TEVA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Teva Pharm Q4 profit tops estimates by one cent

Israel-based Teva Pharmaceutical Industries reported a slightly larger-than-expected rise in fourth-quarter profit on Wednesday and forecast 2020 earnings in line with expectations.

Teva partners with Israeli institutes for early-stage drug research

Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.

Teva Pharm says opioid settlement will not derail ability to cut debt

Teva Pharmaceutical Industries Ltd <TEVA.TA> on Thursday expressed confidence in its ability to continue paying down its huge debt burden even if it is forced to pay billions of dollars to settle thousands of U.S. opioid lawsuits.

Teva Pharm Q3 profit misses estimates, names new CFO

Israel-based Teva Pharmaceutical Industries reported a larger-than-expected drop in third-quarter profit on Thursday and slightly raised its full year outlook.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up